Citations

Showing 10 of 108083 citations.

Real‐time tomosynthesis for radiation therapy guidance
Hsieh, Scott S. , Ng, Lydia W.

Mayo Clinic

Medical Physics | August 24, 2017 | Volume: 44 | Issue: 11 | Pages: 5584-5595

10.1002/mp.12530 | PMID 28837233 Get It

PurposeFluoroscopy has been a tool of choice for monitoring treatments or interventions because of its extremely fast imaging times. However, the contrast obtained in fluoroscopy may be insufficient for certain clinical applications. In stereotactic ablative radiation therapy of the lung, fluoroscopy often lacks sufficient contrast for gating treatment. The purpose of this work is to describe and assess a real‐time tomosynthesis design that can produce sufficient contrast for guidance of lung tumor treatment within a small field of view.MethodsPrevious tomosynthesis designs in radiation oncology have temporal resolution on the order of seconds. The proposed system design uses parallel acquisition of multiple frames by simultaneously illuminating the field of view with multiple sources, enabling a temporal resolution of up to 30 frames per second. For a small field of view, a single flat‐panel detector could be used if different sectors of the detector are assigned to specific sources. Simulated images were generated by forward projection of existing clinical datasets. The authors varied the number of tubes and the power of each tube in order to determine the impact on tumor visualization.ResultsVisualization of the tumor was much clearer in tomosynthesis than in fluoroscopy. Contrast generally improved with the number of sources used, and a minimum of four sources should be used. The high contrast of the lung allows very low system power, and in most cases, less than 1 mA was needed. More power is required in the lateral direction than the AP direction.ConclusionsThe proposed system produces images adequate for real‐time guidance of radiation therapy. The additional hardware requirements are modest, and the system is capable of imaging at high frame rates and low dose. Further development, including a prototype system and a dosimetry study, is needed to further evaluate the feasibility of this device for radiation therapy guidance.
Dependency and AMR Embeddings for Drug-Drug Interaction Extraction from Biomedical Literature
Wang, Yanshan , Wang, Liwei , Shen, Feichen , Liu, Fei , Liu, Sijia , Rastegar-Mojarad, Majid , Liu, Hongfang , Wang, Yanshan

Mayo Clinic

Proceedings of the 8th ACM International Conference on Bioinformatics, Computational Biology,and Health Informatics | August 24, 2017 | Volume: No volume available | Issue: No issue available | Pages: 36-43

10.1145/3107411.3107426 Get It

Investigational drugs in phase II clinical trials for primary biliary cholangitis
Silveira, Marina G., Lindor, Keith D.

Mayo Clinic

Expert Opinion on Investigational Drugs | August 24, 2017 | Volume: 26 | Issue: 10 | Pages: 1115-1121

10.1080/13543784.2017.1371135 | PMID 28836457 Get It

Flow Cytometric Immune Profiling in Infliximab-Associated Tuberculosis
Pennington, Kelly M. , Sasieta, Humberto C., Ramos, Guiherme P, Erskine, Courtney L. , Keulen, Virginia P. Van , Peikert, Tobias, Escalante, Patricio , Ramos, Guilherme Piovezani , Van Keulen, Virginia P, Ramos, Guilherme P

Mayo Clinic

Clinical Medicine Insights: Case Reports | August 24, 2017 | Volume: 10 | Issue: No issue available | Pages: No page available

10.1177/1179547617724776 | PMID 28890660 Get It

Tumor necrosis factor α antagonists are increasingly used to treat inflammatory and autoimmune disorders and are associated with increased risk of active tuberculosis. Diagnosis of active tuberculosis in patients taking tumor necrosis factor α antagonists can be challenging owing to increased incidence of extrapulmonary manifestations and false-negative results on current available diagnostic tests. We present a case of a young woman on infliximab for ulcerative colitis who presented with disseminated tuberculosis. As part of a research study, we performed flow cytometric immune profiling, which has previously not been reported in patients with active tuberculosis taking tumor necrosis α antagonists. The flow cytometry results were within the positive thresholds for tuberculosis infection. Flow cytometric immune profiling may be a valid diagnostic tool for patients taking tumor necrosis factor α antagonists.
Author response: NFATc2 enhances tumor-initiating phenotypes through the NFATc2/SOX2/ALDH axis in lung adenocarcinoma
Xiao, Zhijie , Zhu, Yun , Gao, Xuyuan , Tin, Vicky Pui‐Chi, Wong, Maria Pik , Liu, Jing , Wang, Siqi , Qin, Jing , Wang, Junwen , Wong, Maria Pik

Mayo Clinic

No container title available | August 24, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.26733.032 Get It

Expanded phenotype in a patient with spastic paraplegia 7
Gass, Jennifer , Blackburn, Patrick R. , Jackson, Jessica L. , Macklin, Sarah , Gerpen, Jay Van, Atwal, Paldeep S. , Jackson, Jessica, Van Gerpen, Jay, Atwal, Paldeep S , Gerpen, Jay A. van

Mayo Clinic

Clinical Case Reports | August 24, 2017 | Volume: 5 | Issue: 10 | Pages: 1620-1622

10.1002/ccr3.1109 | PMID 29026558 Get It

Key Clinical MessageHereditary spastic paraplegia is a group of clinically and genetically heterogeneous neurodegenerative disorders, often characterized by weakness and spasticity in the lower limbs. In our study, we describe a spastic paraplegia type 7 patient with an expanded phenotype who was diagnosed after the discovery of pathogenic variants in SPG7.
Clinical verification of genetic results returned to research participants: findings from a Colon Cancer Family Registry
Laurino, Mercy , Truitt, Anjali R. , Tenney, Lederle, Fisher, Douglass, Lindor, Noralane M. , Veenstra, David L. , Jarvik, Gail P. , Laurino, Mercy Y , Jarvik, Gail P , Newcomb, Polly A. , Fullerton, Stephanie M.

Mayo Clinic

Molecular Genetics & Genomic Medicine | August 24, 2017 | Volume: 5 | Issue: 6 | Pages: 700-708

10.1002/mgg3.328 | PMID 29178651 Get It

AbstractBackgroundThe extent to which participants act to clinically verify research results is largely unknown. This study examined whether participants who received Lynch syndrome (LS)‐related findings pursued researchers’ recommendation to clinically verify results with testing performed by a CLIA‐certified laboratory.MethodsThe Fred Hutchinson Cancer Research Center site of the multinational Colon Cancer Family Registry offered non‐CLIA individual genetic research results to select registry participants (cases and their enrolled relatives) from 2011 to 2013. Participants who elected to receive results were counseled on the importance of verifying results at a CLIA‐certified laboratory. Twenty‐six (76.5%) of the 34 participants who received genetic results completed 2‐ and 12‐month postdisclosure surveys; 42.3% of these (11/26) participated in a semistructured follow‐up interview.ResultsWithin 12 months of result disclosure, only 4 (15.4%) of 26 participants reported having verified their results in a CLIA‐certified laboratory; of these four cases, all research and clinical results were concordant. Reasons for pursuing clinical verification included acting on the recommendation of the research team and informing future clinical care. Those who did not verify results cited lack of insurance coverage and limited perceived personal benefit of clinical verification as reasons for inaction.ConclusionThese findings suggest researchers will need to address barriers to seeking clinical verification in order to ensure that the intended benefits of returning genetic research results are realized.
The Metabolic Syndrome and Risk of Sudden Cardiac Death: The Atherosclerosis Risk in Communities Study
Hess, Paul L. , Al‐Khalidi, Hussein R. , Mulder, Hillary , Kucharska‐Newton, Anna , Rosamond, Wayne, Curtis, Lesley H. , Prineas, Ronald J. , Sotoodehnia, Nona , Friedman, Daniel J , Rosamond, Wayne D. , Lópes, Renato D. , Gersh, Bernard J. , Mark, Daniel B. , Post, Wendy S. , Al‐Khatib, Sana M. , Kucharska-Newton, Anna M , Mulder, Hillary

Mayo Clinic

Journal of the American Heart Association | August 24, 2017 | Volume: 6 | Issue: 8 | Pages: No page available

10.1161/jaha.117.006103 | PMID 28835363 Get It

Background Prior studies have demonstrated a link between the metabolic syndrome and increased risk of cardiovascular mortality. Whether the metabolic syndrome is associated with sudden cardiac death is uncertain. Methods and Results We characterized the relationship between sudden cardiac death and metabolic syndrome status among participants of the ARIC (Atherosclerosis Risk in Communities) Study (1987–2012) free of prevalent coronary heart disease or heart failure. Among 13 168 participants, 357 (2.7%) sudden cardiac deaths occurred during a median follow‐up of 23.6 years. Participants with the metabolic syndrome (n=4444) had a higher cumulative incidence of sudden cardiac death than those without it (n=8724) (4.1% versus 2.3%, P <0.001). After adjustment for participant demographics and clinical factors other than components of the metabolic syndrome, the metabolic syndrome was independently associated with sudden cardiac death (hazard ratio, 1.70, 95% confidence interval, 1.37–2.12, P <0.001). This relationship was not modified by sex (interaction P =0.10) or race (interaction P =0.62) and was mediated by the metabolic syndrome criteria components. The risk of sudden cardiac death varied according to the number of metabolic syndrome components (hazard ratio 1.31 per additional component of the metabolic syndrome, 95% confidence interval, 1.19–1.44, P <0.001). Of the 5 components, elevated blood pressure, impaired fasting glucose, and low high‐density lipoprotein were independently associated with sudden cardiac death. Conclusions We observed that the metabolic syndrome was associated with a significantly increased risk of sudden cardiac death irrespective of sex or race. The risk of sudden cardiac death was proportional to the number of metabolic syndrome components.
Improved flare and remission pattern in rheumatoid arthritis over recent decades: a population-based study
Raheel, Shafay , Matteson, Eric L. , Crowson, Cynthia S. , Myasoedova, Elena

Mayo Clinic

Rheumatology | August 23, 2017 | Volume: 56 | Issue: 12 | Pages: 2154-2161

10.1093/rheumatology/kex352 | PMID 28968703 Get It